INS and type 2 diabetes mellitus: To date, several TZDs, including pioglitazone androsiglitazone, improve glycemic control in patients with type 2 diabetes orglucose intolerance via their insulin-sensitizing activity, mainly achieved bypreventing FA uptake and adipose deposition in insulin-sensitive tissues suchas liver, muscle, and pancreas [7, 9–11].